Teh et al. (41), after identifying increased CREB and MCL-1 in treatment-resistant myeloma cells, showed that combining an MCL-1 inhibitor to dexamethasone showed synergistic activity in killing primary myeloma cells from patients. Here, MCL1 is linked to plasma cell myeloma.